JDD Special Focus

Psoriasis

Stay up-to-date on new clinical findings in Psoriasis  View the latest articles, case reports, supplements, CME activities, Podcast episodes and more!

 

Podcast Episodes

What Women Don’t Want … Psoriasis

In this edition of the JDD Podcast, Dr. Adam Friedman is joined by Dr. Deirdre Hooper, Associate Clinical Professor in the Department of Dermatology at both Louisiana State University and Tulane University, to discuss her article “Impact of Psoriasis on Women” in the September 2019 issue of the JDD on the unique considerations for the adult female psoriasis patient.

What questions should you be asking? What matters most when discussing therapeutic options? What is the best way to partner to ensure a long term relationship? If we could read minds this podcast would not be necessary but alas, it sorely is. Check it out!

Picking up on Prescribing Patterns for Psoriasis: A Real Deal Assessment

We (and our patients) are fortunate to live during a time when we have many safe and effective options to treat a chronic inflammatory skin disease such as Psoriasis. We are reminded of this, nay inundated, with warm and fuzzy headlines in the lay dermatology press that humblebrag said efficacy. However, how does this translate to the real world, when the perfect, neat lines of clinical trials are blurred by practical issues such as access, patient and practitioner perception, and long term use and efficacy? In a JDD Podcast first, we had not one but two investigators share their work and first steps to evaluate just that.

To Treat or Not To Treat: Systemic Therapy Considerations for Psoriasis in the Setting of Malignancy

I’m a biologic girl in a biologic world…or so I think myself and never say out loud when reviewing therapeutic options for moderate to severe psoriasis. We are so fortunate to have so many wonderful options, however certain clinical scenarios may limit our ability to capitalize on said armament mostly due to limited experience and data. Enter previous malignancy – in most phase 3 studies these patients are weeded out or the history of malignancy must be at least 5 years prior to entry. So what to do? Our colleagues at Tufts Medical Center asked this very question. Tune in to hear what Dr. David Rosmarin, Assistant Professor of Dermatology and Residency Program Director learned from performing a retrospective chart review and how his work and his experience guides his clinical decision making when managing psoriasis. Don’t flake (or is it scale?)….check it out.

Ask the Investigator: Shedding Some Light on Phototherapy Protocols for Psoriasis and Tips to Improve Patient Screening and Treatment

In this edition of the JDD Podcast, Dr. Adam Friedman reviews phototherapy protocols and pearls with psoriasis expert Dr. Jashin Wu, Director of Research at Kaiser Permanente based on his study published in the August 2016 Journal of Drugs in Dermatology titled “Comparison of Phototherapy Guidelines for Psoriasis: A Critical Appraisal and Comprehensive Review.” Also tune in to hear how Dr. Wu counsels his psoriasis patients on psoriasis comorbidities and initiates, and manages them with phototherapy, topicals, and systemic immunosuppressants.

Sponsored

CME Library

Learning objectives: Upon completion of this enduring activity, participants should be able to discuss prescribing  patterns associated with biologic therapies for psoriasis and utilization of concomitant non-biologic psoriasis therapies in patients on biologics.

 

Take CME Now

Translational Lecture Series

Targeting cAMP Signaling for the Treatment of Inflammatory Diseases of the Skin

Dr. Jon Zippin, Assistant Attending Dermatologist and Assistant Professor of Dermatology at Weill Medical College of Cornell, elucidates the complexity of cAMP biology and the translational impact of PDE4 inhibition as it relates to chronic inflammatory skin diseases. Tune in to learn why targeting this pathway is clinically meaningful but also where more work is needed to improve outcomes.

Psoriasis: Biological Basis for Comorbidities

Dr. Abrar Qureshi, Professor and Chair of Department of Dermatology at The Warren Alpert Medical School of Brown University, reviews his research to uncover the biological basis for many of the co-morbidities associated with, and risk factors for, psoriasis. Through this clear and clinically oriented presentation, the common pathophysiological threads are elucidated with a focus on identifying preventive strategies and therapeutic targets for current and future treatments.

Articles

Evaluation of Patient-Reported Outcomes with Etanercept in Moderate to Severe Plaque Psoriasis Patients After Therapy With Apremilast

Patients with moderate-to-severe psoriasis can have symptoms resulting in significant impact on patient-reported outcomes (PROs). The effect of etanercept (ETN) in moderate-to-severe psoriasis patients who previously received apremilast (APR) was studied, including impact on PRO endpoints.

Read Now

Recapture Rate of Brodalumab in Patients With a Lapse in Treatment

This review discusses the efficacy and safety of brodalumab and other biologic therapies in patients with psoriasis who stop and restart treatment. These clinically relevant and important findings can help inform real-world treatment decisions.

Read Now

View all Articles

Sponsored

Case Reports

Rapid and Sustained Improvement in a Patient With Plaque Psoriasis Switched to Brodalumab After Failing Treatment Clearance on Six Other Biologic Therapies

 To date, there are few guidelines to help physicians select the optimal biology agent and none that have looked specifically at plantar psoriasis. For this patient, finding a biologic that worked and was tolerable was a process of trial and error that took four years. The results achieved in this previously refractory patient with difficult-to-treat psoriasis may be due to the unique mechanism of action of brodalumab, though this will need to be confirmed in larger studies.

Read Now

Successful Treatment of Refractory Plaque-Type Psoriasis and Psoriatic Arthritis With Guselkumab and Adalimumab Combination Therapy: A Case Report

Herein, we report a case of a 46-year-old woman with a 12-year history of severe plaque psoriasis and psoriatic arthritis who was treated successfully with guselkumab and adalimumab after failure of prior topical corticosteroids, cyclosporine and narrow-band ultraviolet B (NBUVB) phototherapy.

Read Now

View all Case Reports

Supplements

Do You Know the Most Complete, Targeted Biologic for Psoriasis? The Answer May Surprise You

When today’s dermatology residents were born, the concept of psoriasis as a systemic disease was relatively new. Early in the 1980s, topical therapy was the mainstay for medical management of this “skin condition.” Systemic therapies were beginning to be used for severe psoriasis, although it was unclear how they provided benefit. Three decades later, dermatologists have a much better—though perhaps still incomplete—understanding of the pathogenesis of psoriasis and its related comorbidities. Novel therapies have emerged to target the immunologic drivers at the heart of the disease

Read Now

IL-23 Versus IL-17 in the Pathogenesis of Psoriasis: There Is More to the Story Than IL-17A

In this paper, we describe the importance of the TH17 pathway in psoriasis pathogenesis with a focus on the roles of IL-23 and IL-17 within this pathway. We also discuss the different IL-17 subtypes involved in psoriasis immunopathology and the multitude of cells that can produce these subtypes. Finally, we examine treatments that inhibit IL-23 and IL-17.

Read Now

Think You Know IL-17 Pathway? Think Again

When today’s dermatology residents were born, the concept of psoriasis as a systemic disease was relatively new. Early in the 1980s, topical therapy was the mainstay for medical management of this “skin condition.” Systemic therapies were beginning to be used for severe psoriasis, although it was unclear how they provided benefit. Three decades later, dermatologists have a much better—though perhaps still incomplete—understanding of the pathogenesis of psoriasis and its related comorbidities. Novel therapies have emerged to target the immunologic drivers at the heart of the disease.

Read Now

View all Supplements

Dermatology News

Colloidal Oatmeal Part I: Clinical Efficacy in the Treatment of Atopic Dermatitis

| Atopic Dermatitis, Featured Articles, The Latest | No Comments
Colloidal oatmeal has a long-standing history in the treatment of dermatologic disease. It is composed of various phytochemicals, which contribute to its wide-ranging function and clinical use. It has various…

Oral Collagen Supplementation: A Systematic Review of Dermatological Applications

| Featured Articles | No Comments
Nutrition is thought to play an important role in skin homeostasis. The use of nutraceuticals or “functional foods” in skincare along with technological innovations within the food industry has been…

Treating the AD Patient During COVID-19

| Podcast Highlights | No Comments
iTunes Google Play Stitcher TuneIn Dr. Peter Lio and Dr. Adam Friedman   Atopic dermatitis is a relentless, recurring, unreasonable, often recalcitrant inflammatory skin disease that impacts millions of children…

Revisiting Handwashing – As It Is Absolutely Essential

| Featured Articles, Global Health, The Latest | No Comments
As the coronavirus pandemic continues into the second half of 2020, states across the US remain steadfast in their search to determine the safest methods of returning to normalcy. Without…